Can dapagliflozin be started in a patient who recently underwent angioplasty for myocardial infarction and is currently in the ICU being treated for pneumonia?

Dapagliflozin Should NOT Be Started in This ICU Patient with Pneumonia

Do not initiate dapagliflozin in your post-angioplasty myocardial infarction patient who is currently in the ICU being treated for pneumonia. The drug must be withheld during acute illness with reduced oral intake, fever, or infection, and the patient must be hemodynamically stable before initiation 1, 2.

Critical Contraindications in This Clinical Scenario

Acute Illness Exclusion Criteria

• Pneumonia represents an acute intercurrent illness requiring hospitalization, which is an absolute contraindication to dapagliflozin initiation 1, 2
• The drug must be withheld during any acute illness with fever, reduced food/fluid intake, or infection to prevent euglycemic diabetic ketoacidosis and volume depletion 1
• Patients in the ICU are by definition not hemodynamically stable enough for SGLT2 inhibitor initiation 2

Hemodynamic Stability Requirements

• Dapagliflozin should only be started once the patient is stabilized, defined as systolic blood pressure >95-100 mmHg, no IV vasodilators or increased IV diuretics in the past 6 hours, and no IV inotropes in the past 24 hours 2
• The drug is contraindicated in patients with hemodynamic instability or those requiring vasopressors/IV inotropics 2
• ICU patients with pneumonia often have volume depletion from fever, reduced oral intake, and infection—all of which increase the risk of excessive volume depletion when combined with dapagliflozin's osmotic diuretic effect 1, 3

Evidence from Post-MI Trials

Limited Benefit in Non-Diabetic, Non-Heart Failure Post-MI Patients

• The 2025 ACC/AHA Acute Coronary Syndromes Guidelines state that in patients without diabetes or heart failure, dapagliflozin was not beneficial after myocardial infarction 4
• The DAPA-MI trial showed that dapagliflozin reduced new-onset diabetes and heart failure symptoms in patients with prediabetes, but the primary cardiovascular benefit was not demonstrated in normoglycemic patients without heart failure 5
• The guidelines note that SGLT2 inhibitors have well-documented benefits in stable patients with established heart failure or chronic kidney disease, but have not been adequately studied early after acute coronary syndromes 4

Perioperative and Acute Illness Risks

• Due to higher risk of diabetic and euglycemic ketoacidosis in the perioperative period and during acute illness, dapagliflozin should be stopped at least 3 days prior to scheduled surgery and withheld during any acute illness 4, 3
• SGLT2 inhibitors may increase the risk of urinary tract infection, genital mycotic infection, hypovolemia, and acute kidney injury during acute illness 4

When to Consider Dapagliflozin After Recovery

Post-Discharge Initiation Criteria

• Wait until the patient has fully recovered from pneumonia, is eating and drinking normally, and has been discharged from the ICU 1
• Reassess for specific indications: type 2 diabetes with eGFR ≥25 mL/min/1.73 m², established heart failure (especially HFrEF), or chronic kidney disease with albuminuria (UACR ≥200 mg/g) 1
• If the patient develops heart failure post-MI or has diabetes with CKD, dapagliflozin 10 mg daily can be initiated once clinically stable, with documented cardiovascular and renal benefits 1

Monitoring After Acute Illness Resolution

• Before initiating dapagliflozin post-recovery, check eGFR (must be ≥25 mL/min/1.73 m² for cardiovascular/renal protection), assess volume status, and correct any depletion 1, 3
• Consider reducing concurrent diuretic doses at initiation to prevent excessive volume depletion, especially in elderly patients 1

Common Pitfalls to Avoid

• Do not start dapagliflozin "early" in the post-MI period if the patient has an acute intercurrent illness—the trials that support in-hospital initiation (DAPA-ACT HF-TIMI 68, EMPULSE) specifically excluded patients with active infection or hemodynamic instability 6, 7
• Do not assume that post-angioplasty status alone is an indication for dapagliflozin—the drug requires either diabetes, heart failure, or CKD with albuminuria for evidence-based benefit 4, 1
• Do not initiate during the ICU stay for pneumonia treatment, as this violates both the acute illness exclusion and hemodynamic stability requirements 1, 2